The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis
Open accessAbstract
BACKGROUND: Severe atopic dermatitis (AD) has a high unmet need for effective and safe therapeutics. In early-phase trials, dupilumab, a fully human mAb targeting IL-4 receptor α, markedly improved disease activity, but the effect of IL-4/IL-13 blockade on AD at the molecular level has not been characterized. OBJECTIVES: We sought to evaluate dupilumab modulation of the AD molecular signature. METHODS: We performed transcriptomic analyses of pretreatment and posttreatment skin biopsy specimens from patients with moderate-to-severe AD treated weekly with 150 or 300 mg of dupilumab or placebo. RESULTS: Exacerbation of the AD transcriptome was observed in placebo-treated patients. Dupilumab improved the AD signature in a dose-dependent manner. Expression of genes upregulated in AD lesions decreased in patients treated with dupilumab by 26% (95% CI, 21% to 32%) and 65% (95% CI, 60% to 71%) for treatment with 150 and 300 mg, respectively. Genes downregulated in AD lesions increased by 21% (95% CI, 16% to 27%) and 32% (95% CI, 26% to 37%) with dupilumab (150 and 300 mg, respectively). The molecular changes paralleled improvements in clinical scores. A dupilumab treatment signature of 821 probes (>2-fold change, P < .05) significantly modulated in the 300-mg dupilumab group at week 4 compared with baseline was identified in this sample set. Significant (P < .05) decreases in mRNA expression of genes related to hyperplasia (K16 and MKI67), T cells, and dendritic cells (CD1b and CD1c) and potent inhibition of TH2-associated chemokines (CCL17, CCL18, CCL22, and CCL26) were noted without significant modulation of TH1-associated genes (IFNG). CONCLUSIONS: This is the first report showing rapid improvement of the AD molecular signature with targeted anti-IL-4 receptor α therapy. These data suggest that IL-4 and IL-13 drive a complex, TH2-centered inflammatory axis in patients with AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Williams, H. C., Leung, D. Y. M., Thestrup‐Pedersen, K., & David, T. J. (2000) · Cited by 4,599
Bieber, T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra074081 · Cited by 1,780
A Model-Based Background Adjustment for Oligonucleotide Expression Arrays
Wu, Z., Irizarry, R. A., Gentleman, R., Martinez-Murillo, F., & Spencer, F. (2004) · Journal of the American Statistical Association · doi:10.1198/016214504000000683 · Cited by 1,716
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, L. A., Thaçi, D., Hamilton, J. D., Graham, N. M., Bieber, T., Rocklin, R., Ming, J. E., Ren, H., Kao, R., Simpson, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314768 · Cited by 1,421
Self-citationDupilumab in Persistent Asthma with Elevated Eosinophil Levels
Wenzel, S., Ford, L., Pearlman, D., Spector, S., Sher, L., Skobieranda, F., Wang, L., Kirkesseli, S., Rocklin, R., Bock, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304048 · Cited by 1,320
Self-citationThe eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.100102.x · Cited by 1,200
Cytokine modulation of atopic dermatitis filaggrin skin expression
Howell, M. D., Kim, B. E., Gao, P., Grant, A. V., Boguniewicz, M., DeBenedetto, A., Schneider, L., Beck, L. A., Barnes, K. C., & Leung, D. Y. M. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.04.031 · Cited by 1,084
Atopic dermatitis: a disease of altered skin barrier and immune dysregulation
Boguniewicz, M., & Leung, D. Y. M. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01027.x · Cited by 1,073
Gittler, J. K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K. J., Wang, C. Q. F., Mitsui, H., Cardinale, I., de Guzman Strong, C., Krueger, J. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.012 · Cited by 981
Self-citationTh2 Cytokines and Atopic Dermatitis
B. Brandt, E. (2011) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000110 · Cited by 655
Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6
Kim, B. E., Leung, D. Y. M., Boguniewicz, M., & Howell, M. D. (2008) · Clinical Immunology · doi:10.1016/j.clim.2007.11.006 · Cited by 538
Suárez-Fariñas, M., Dhingra, N., Gittler, J., Shemer, A., Cardinale, I., de Guzman Strong, C., Krueger, J. G., & Guttman-Yassky, E. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.04.046 · Cited by 483
Self-citationDeciphering the complexities of atopic dermatitis: Shifting paradigms in treatment approaches
Leung, D. Y. M., & Guttman-Yassky, E. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.08.008 · Cited by 474
Self-citationSuárez-Fariñas, M., Tintle, S. J., Shemer, A., Chiricozzi, A., Nograles, K., Cardinale, I., Duan, S., Bowcock, A. M., Krueger, J. G., & Guttman-Yassky, E. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.12.1124 · Cited by 464
Self-citationTranscriptional regulation by STAT6
Goenka, S., & Kaplan, M. H. (2011) · Immunologic Research · doi:10.1007/s12026-011-8205-2 · Cited by 429
Sowden, J. M., Allen, B. R., Berth-Jones, J., Graham-Brown, R. A. C., Motley, R. J., Finlay, A. Y., Salek, M., Marks, R., Ross, J. S., & Camp, R. D. R. (1991) · The Lancet · doi:10.1016/0140-6736(91)90134-b · Cited by 411
Contrasting pathogenesis of atopic dermatitis and psoriasis—Part I: Clinical and pathologic concepts
Guttman-Yassky, E., Nograles, K. E., & Krueger, J. G. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.01.053 · Cited by 384
Self-citationA Population-Based Survey of Eczema Prevalence in the United States
Hanifin, J. M., & Reed, M. L. (2007) · Dermatitis · doi:10.2310/6620.2007.06034 · Cited by 349
Danso, M. O., van Drongelen, V., Mulder, A., van Esch, J., Scott, H., van Smeden, J., El Ghalbzouri, A., & Bouwstra, J. A. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.83 · Cited by 330
Guttman-Yassky, E., Nograles, K. E., & Krueger, J. G. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.01.054 · Cited by 314
Self-citationThe Socioeconomic Impact of Atopic Dermatitis in the United States: A Systematic Review
Mancini, A. J., Kaulback, K., & Chamlin, S. L. (2008) · Pediatric Dermatology · doi:10.1111/j.1525-1470.2007.00572.x · Cited by 241
Th2 Cytokines Act on S100/A11 to Downregulate Keratinocyte Differentiation
Howell, M. D., Fairchild, H. R., Kim, B. E., Bin, L., Boguniewicz, M., Redzic, J. S., Hansen, K. C., & Leung, D. Y. M. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.74 · Cited by 224
Tintle, S., Shemer, A., Suárez-Fariñas, M., Fujita, H., Gilleaudeau, P., Sullivan-Whalen, M., Johnson-Huang, L., Chiricozzi, A., Cardinale, I., Duan, S., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.05.042 · Cited by 220
Self-citationIL-4 Regulates Skin Homeostasis and the Predisposition toward Allergic Skin Inflammation
Sehra, S., Yao, Y., Howell, M. D., Nguyen, E. T., Kansas, G. S., Leung, D. Y. M., Travers, J. B., & Kaplan, M. H. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901860 · Cited by 195
Khattri, S., Shemer, A., Rozenblit, M., Dhingra, N., Czarnowicki, T., Finney, R., Gilleaudeau, P., Sullivan-Whalen, M., Zheng, X., Xu, H., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.03.003 · Cited by 180
Self-citationIL-17A as an Inducer for Th2 Immune Responses in Murine Atopic Dermatitis Models
Nakajima, S., Kitoh, A., Egawa, G., Natsuaki, Y., Nakamizo, S., Moniaga, C. S., Otsuka, A., Honda, T., Hanakawa, S., Amano, W., et al. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.51 · Cited by 169
Zachariae, R., Zachariae, C., Ibsen, H. H., Mortensen, J. T., & Wulf, H. C. (2004) · Acta Dermato-Venereologica · doi:10.1080/00015550410023284 · Cited by 164
Cole, C., Kroboth, K., Schurch, N., Sandilands, A., Sherstnev, A., O’Regan, G. M., Watson, R. M., McLean, W. H. I., Barton, G. J., Irvine, A. D., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.04.021 · Cited by 151
Efalizumab for severe atopic dermatitis: A pilot study in adults
Takiguchi, R. H., Tofte, S. J., Simpson, B., Harper, E., Blauvelt, A., Hanifin, J. M., & Simpson, E. L. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.08.031 · Cited by 92
Quality-of-life Outcomes and Measurement in Childhood Atopic Dermatitis
Chamlin, S. L., & Chren, M. (2010) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2010.05.004 · Cited by 84
Izuhara, K., Arima, K., & Yasunaga, S. (2002) · Current Drug Targets - Inflammation & Allergy · doi:10.2174/1568010023344661 · Cited by 78
Quality of life of children with atopic dermatitis and their families
McKenna, S. P., & Doward, L. C. (2008) · Current Opinion in Allergy & Clinical Immunology · doi:10.1097/aci.0b013e3282ffd6cc · Cited by 74
Harshlight: a "corrective make-up" program for microarray chips
Suárez‐Fariñas, M., Pellegrino, M., Wittkowski, K. M., & Magnasco, M. O. (2005) · BMC Bioinformatics · doi:10.1186/1471-2105-6-294 · Cited by 70
Self-citationBao, L., Shi, V. Y., & Chan, L. S. (2012) · Cytokine · doi:10.1016/j.cyto.2012.10.031 · Cited by 69
Suizidgedanken, Angst und Depression bei erwachsenen Neurodermitikern
Dieris-Hirche, J., Gieler, U., Kupfer, J., & Milch, W. E. (2009) · Der Hautarzt · doi:10.1007/s00105-009-1744-y · Cited by 65
Alefacept for moderate to severe atopic dermatitis: A pilot study in adults
Moul, D. K., Routhouska, S. B., Robinson, M. R., & Korman, N. J. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.02.007 · Cited by 64
Prevalence of Suicidal Ideation in Patients with Atopic Dermatitis
Kimata, H. (2006) · Suicide and Life-Threatening Behavior · doi:10.1521/suli.2006.36.1.120 · Cited by 63
Dhingra, N., Gulati, N., & Guttman‐Yassky, E. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.239 · Cited by 35
Self-citationRozenblit, M., Suárez‐Fariñas, M., Shemer, A., Khattri, S., Gilleaudeau, P., Sullivan-Whalen, M. M., Zheng, X., Xu, H., Cardinale, I. R., Krueger, J. G., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.05.024 · Cited by 22
Self-citation
Cited by
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Self-citationTargeting key proximal drivers of type 2 inflammation in disease
Gandhi, N. A., Bennett, B. L., Graham, N. M. H., Pirozzi, G., Stahl, N., & Yancopoulos, G. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd4624 · Cited by 766
Self-citationGuttman-Yassky, E., Bissonnette, R., Ungar, B., Suárez-Fariñas, M., Ardeleanu, M., Esaki, H., Suprun, M., Estrada, Y., Xu, H., Peng, X., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.08.022 · Cited by 697
Self-citationNoda, S., Suárez-Fariñas, M., Ungar, B., Kim, S. J., de Guzman Strong, C., Xu, H., Peng, X., Estrada, Y. D., Nakajima, S., Honda, T., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.08.015 · Cited by 657
Self-citationThe immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies
Brunner, P. M., Guttman-Yassky, E., & Leung, D. Y. M. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.01.011 · Cited by 642
Self-citation
Metadata
- Authors
- Hamilton, J. D., Suárez-Fariñas, M., Dhingra, N., Cardinale, I., Li, X., Kostic, A., Ming, J. E., Radin, A. R., Krueger, J. G., Graham, N., Yancopoulos, G. D., Pirozzi, G., & Guttman-Yassky, E.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2014-12
- Volume
- 134
- Issue
- 6
- Pages
- 1293-1300
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2012868073
- Cited by
- 469
- References
- 39
- FWCI
- 34.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.